Table 1. Clinical characteristics of surgically resected stage IV patients.
| Variable | Total (n=88) |
|---|---|
| Sex, n (%) | |
| Male | 54 (61.4) |
| Female | 34 (38.6) |
| Age at surgery, n (%) | |
| <60 years | 53 (60.2) |
| ≥60 years | 35 (39.8) |
| Smoking history, n (%) | |
| Yes | 37 (42.0) |
| No | 51 (58.0) |
| CCI score, n (%) | |
| 0–1 | 84 (95.5) |
| 2–3 | 4 (4.5) |
| cT stage, n (%) | |
| T1 | 22 (25.0) |
| T2 | 43 (48.9) |
| T3 | 10 (11.4) |
| T4 | 13 (14.8) |
| pT stage, n (%) | |
| T1 | 13 (14.8) |
| T2 | 26 (29.6) |
| T3 | 14 (15.9) |
| T4 | 35 (39.8) |
| cN stage, n (%) | |
| N0 | 61 (69.3) |
| N1 | 4 (4.5) |
| N2 | 20 (22.7) |
| N3 | 3 (3.4) |
| pN stage, n (%) | |
| N0 | 24 (27.3) |
| N1 | 10 (11.4) |
| N2 | 51 (58.0) |
| N3 | 3 (3.4) |
| Tumor location, n (%) | |
| Left lung | 39 (44.3) |
| Right lung | 49 (55.7) |
| Surgical approach, n (%) | |
| VATs or robots | 35 (39.8) |
| Thoracotomy or conversion | 53 (60.2) |
| Histology, n (%) | |
| Adenocarcinoma | 68 (77.3) |
| Squamous cell carcinoma | 11 (12.5) |
| Others† | 9 (10.2) |
| Metastatic sites, n (%) | |
| Pleural metastases | 35 (39.8) |
| 1–3 brain metastases | 18 (20.5) |
| 1–3 extra-brain metastases | 25 (28.4) |
| Multiple metastases | 10 (11.4) |
| Mutation test, n (%) | |
| EGFR/ALK/ROS1 positive‡ | 38 (43.2) |
| EGFR/ALK/ROS1 negative | 40 (45.5) |
| Unknown | 10 (11.4) |
†: 6 adenosquamous carcinomas, 2 large cell carcinomas, 1 polymorphic cell carcinomas; ‡: 36 cases with EGFR mutation, 1 case with ALK rearrangements and 1 case with ROS1 rearrangements. CCI, Charlson comorbidity index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.